Oncology and Hematology

Episodes 1-16 of 103

• 

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  RestartResume

  Mastering the Sequence: CELMoDs Across Treatment Lines

  MinuteCE®

  Mastering the Sequence: CELMoDs Across Treatment Lines

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  MinuteCE®

  Safety First: Navigating CELMoD-Associated Toxicities

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Why CELMoDs Matter in Myeloma

  RestartResume

  Why CELMoDs Matter in Myeloma

  MinuteCE®

  Why CELMoDs Matter in Myeloma

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  MinuteCE®

   Real-World Ready: Practical Tips for Community Oncologists

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  RestartResume

  Data Dive: Clinical Evidence Behind CELMoDs

  MinuteCE®

  Data Dive: Clinical Evidence Behind CELMoDs

  1.00 program credit

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  MinuteCE®

  Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity

  1.00 credit 10 episodes

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  • 

    

    Noopur Raje, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  MinuteCE®

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  1.00 program credit

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  MinuteCE®

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Sagar Lonial, MD, FACP

  1.00 program credit

• 

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  MinuteCE®

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  1.00 program credit

  • 

    

    Joshua Richter, MD

  • 

    

    Noopur Raje, MD

  1.00 program credit

• 

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  RestartResume

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  CME/CE

  Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach

  0.25 credits

  • 

    

    Heather Wakelee, MD, FASCO

  0.25 credits

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• Prev
• 1
• 2
• 3
• …
• 6
• 7
• Next